Info

AVI BioPharma, Inc. (AVI) is a biopharmaceutical company developing therapeutic products principally based on third-generation NeuGene antisense technology. The Company’s principal products in development target life-threatening diseases, including cardiovascular, infectious, and genetic diseases. AVI’s lead product candidate, Resten-NG is targeted at cardiovascular disease. AVI has completed pre-clinical and some clinical studies using its NeuGene drugs in the treatment of cardiovascular disease, infectious disease, cancer, polycystic kidney disease (PKD), in regulating drug metabolism via the P450 cytochrome system. The Company is conducting a Phase Ib/II clinical trial for coronary artery bypass grafting in eastern Europe. It is also conducting a proof of concept study in boys with Duchenne Muscular Dystrophy (DMD) in the United Kingdom, in collaboration with the MDEX consortium. In March 2008, the Company completed the acquisition of Ercole Biotechnology Inc.